Information about Temazepam
Temazepam is an orally available benzodiazepine used in the therapy of insomnia.
Liver safety of Temazepam
As with most benzodiazepines, temazepam therapy has not been associated with serum aminotransferase or alkaline phosphatase elevations, and clinically apparent liver injury from temazepam has not been reported and must be very rare, if it occurs at all.
Mechanism of action of Temazepam
Temazepam (tem az' e pam) is a benzodiazepine that is widely used as a sleeping aid in the therapy of insomnia. The soporific activity of the benzodiazepines is mediated by their ability to enhance gamma-aminobutyric acid (GABA) mediated inhibition of synaptic transmission through binding to the GABA A receptor.
FDA approval information for Temazepam
Temazepam was approved in the United States in 1981, and currently more than 8 million prescriptions are filled yearly.
Clinical use of Temazepam
Current indications are for the short term treatment of insomnia.
Dosage and administration for Temazepam
Temazepam is available in capsules of 7.5, 15, 22 and 30 mg in several generic forms and under the brand name Restoril. The recommended initial dose for insomnia is 7.5 mg before bedtime, increasing as needed to a maximum dose of 30 mg.
Side effects of Temazepam
The most common side effects of temazepam are dose related and include daytime drowsiness, lethargy, ataxia, dysarthria and dizziness. Tolerance develops to these side effects, but tolerance may also develop to the effects on insomnia
- Diazepam (Oral)
Drug class for Temazepam